GLP-1 Market Size, Share & Trends Analysis Report By Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist, Short-acting GLP-1 Agonist), By Type of Agonist (Single Agonist, Dual Agonist, Tri-agonist), By Molecule Type (Biologic Peptide GLP-1 Agonists, Small-Molecule Non-Peptide GLP-1 Agonists), By Active Compound (Semaglutide, Tirzepatide, Dulaglutide, Liraglutide, Lixisenatide, Exenatide, Orforglipron, Retatrutide, Survodutide, Other Active Compounds), By Route of Administration (Oral, Parenteral), By Dosing Frequency (Daily, Weekly, Monthly or Extended-Interval), By Delivery System, By Target Indication, By Payer, By Region and By Segments Forecasts, 2026 to 2035
Youre seeing progress toward your health goalswhether thats steadier blood sugar, improved symptoms, or other changes that matter to you
GLP-1 receptors in the mesolimbic dopamine system particularly the ventral tegmental area and nucleus accumbens modulate the dopamine release that reinforces addictive behavior
And thats all it takes
Medication is billed separately by the pharmacy and included within the total program price as posted above